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ABSTRACT 
Pain is an unpleasant sensation experienced by all individuals and classified as acute and chronic pain. NSAID’s were most widely 
used for treatment of Analgesia and Inflammation. Ibuprofen, Ketoprofen, Polyethylene glycol 1500 & PEG 6000 were used as drug 
carriers and Glycine was used as spacer to link the drugs through ester linkage. Ibuprofen and Ketoprofen belong to propionic acid 
derivatives of Anti-inflammatory drugs and are non-selective COX inhibitors. PEG 1500/PEG6000-Ibuprofen/Ketoprofen and PEG 
1500/PEG 6000-Glycine-Ibuprofen/Ketoprofen were synthesized and are subjected to In Vitro dissolution studies which revealed 
that the drug release was higher at 7.2 pH rather than at 1.2 pH. The results of In Vivo evaluation studies of both synthesized 
prodrugs revealed that these prodrugs retained their Analgesic activity by hot plate method and acetic acid method, Anti-
inflammatory activity by paw edema method and cotton pellet method. Both the prodrugs had exhibited good ulcer protective 
activity when compared to parent drugs. 
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INTRODUCTION 
Pain is an unpleasant sensation experienced by all 
individuals may be after an injury. Pain is classified as 
acute pain and chronic pain. Acute pain is a localized 
short term pain after an injury, which can be controlled 
by using NSAID’s, where as chronic pain is long term 
pain lasting from days to months, where NSAID’s have 
to be used for long term
1-4, 12-13. NSAID’s were used 
most widely all over the world for treatment of analgesia 
and inflammation
5
.  
Inflammation is a host defense mechanism, which 
involves a complex network of cell-cell, cell-mediator 
and tissue interactions. Inflammation is regarded as an 
injury to cell or tissue after trauma or post operative 
surgery. Prostaglandins play an important role in the 
inflammation process. The mechanism of all NSAID 
drugs is by inhibiting cyclooxygenase (COX) enzyme 
which is required for conversion of arachidonic acid to 
prostaglandin E2 (PGE2). COX enzyme occurs in two 
forms COX1 (cyclooxygenase1) and COX2 
(cyclooxygenase2)
1, 6-11
. Inhibition of COX2 enzymes 
led to anti-inflammatory activity, whereas COX1 for 
ulcer protective activity
4, 12
. Ibuprofen and Ketoprofen 
belongs to Propionic acid derivatives of NSAID 
classification
14
. 
Prodrugs are the compounds which are inactive 
themselves, but are converted to active form at the site 
of action. They are useful in overcoming the problems 
viz poor membrane permeability, toxicity, taste, shorter 
duration of action etc. These prodrugs are converted into 
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their active form by enzyme degradation in the body. 
Prodrugs are the molecules which undergo chemical or 
biochemical conversion before exerting pharmacological 
activity
15
. The main reason for designing prodrugs are to 
overcome the adverse effects or limitations, which are 
associated with parent drugs, such as stability, 
absorption, solubility, rapid elimination, lack of target 
delivery
16
. 
Most commonly prodrugs require hydrolytic cleavage 
mediated by enzymatic catalysis. The drugs containing 
carboxyl, hydroxyl or amino groups are converted to 
prodrug esters or amides from which the drug is 
hydrolyzed by enzymes like esterases and peptidases. 
Ideal properties of prodrug include 
1. Rapid transformation chemically/enzymatically 
cleaved into active form. 
2. Does not have intrinsic pharmacological activity. 
3. Metabolic fragment apart from active drug should 
be nontoxic. 
4. Obtain drug targeting using site specific 
biotransformation/site specific transporters.  
An approach for designing usage of drugs with 
improved therapeutic use was developing polymeric 
prodrugs or polymer-drug conjugates. Any polymer can 
be covalently attached to any class of drugs promising 
better drug characteristics and activity
17
.  
Ideal properties required for polymer  
1. It should be inert 
2. Non toxic, Non immunogenic 
3. Functional groups required for covalent binding 
4. Availability 
5. Bio compatibility, biodegradable, easily excreted17-26. 
Classification of Polymers 
Polymers with carbon chain backbone: Poly 
ethyleneglycol, poly propylene, polystyrene, poly (vinyl 
alcohol), polyacrylamide, poly vinyl pyrrolidone (PVP). 
Polymeric prodrugs was first proposed by H. Ringsdorf 
1975 which involves drug, polymeric backbone as 
carrier and spacer linked to drug with polymeric 
backbone
20, 24, 27-29
.  
Drug
Drug
Carrier Biodegradable
Spacer
Homing
Device
The Ringsdorf model
Figure 1:
13
 
Objective 
Based on the literatures synthesis of prodrugs was aimed 
by using Poly ethylene glycol 1500 and Poly ethylene 
glycol 6000 as polymeric backbone and Glycine an 
amino acid as spacer.  
MATERIAL AND METHODS 
Poly ethylene glycol 1500/6000, Ibuprofen, Ketoprofen, 
Pyridine, Thionyl chloride, Dicyclohexyl carbodiimide, 
Dimethyl amino pyridine, Dimethyl formamide, Diethyl 
ether. 
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Preparation of PEG (1500 & 6000)-Ibuprofen and 
Ketoprofen 
Accurately weighed 1.5 g of PEG 1500/6000 and 1.6 ml 
of pyridine were taken in a round bottom flask, to it 1 g 
accurately weighed DCC (dicyclohexyl carbodiimide) 
and 0.6 g of DMAP (dimethyl amino pyridine) 
previously dissolved in 10 ml of DMF (dimethyl 
formamide) was taken.. The flask was then kept in an ice 
bath and the temperature was maintained at 0
o
 C. To the 
flask 0.5 g of the drugs (Ibuprofen and Ketoprofen) was 
added, slowly for 10 min. The contents of the flask were 
stirred for 7 days to complete the coupling reaction using 
magnetic stirrer at room temperature. The product 
obtained was dissolved in dichloro methane and dried 
over anhydrous potassium carbonate and filtered. The 
filtrate was then treated with Neutral Alumina and then 
reprecipitated by excess of cold Diethyl ether
30
.   
 Preparation of PEG (1500 & 6000)-Glycine-
Ibuprofen and Ketoprofen  
Accurately weighed 1 g of DCC and 0.6 g of DMAP 
were taken in different beakers and dissolved in 10 ml of 
DMF individually. Then DMAP solution was added to 
DCC solution. Accurately weighed 0.4 g of PEG 
1500/6000-Glycine was taken in a beaker and dissolved 
in 20 ml of DMF. The above solution of DCC and 
DMAP was added to PEG 1500/6000-Glycine solution 
drop by drop. Accurately weighed 1 g of drug 
(Ibuprofen and Ketoprofen) was added to the above 
solution and the temperature was maintained at 0
o
 C for 
10 min. The contents were transferred to a round bottom 
flask with a magnetic bead and fitted with a condenser. 
The flask was placed on a magnetic stirrer. The coupling 
reaction was carried out for 7 days at room temperature. 
The filtrate was then treated with Neutral Alumina and 
reprecipitated by excess of cold Diethyl ether.  
All the synthesized compounds i.e. PEG1500-Ibuprofen, 
PEG6000-Ibuprofen, PEG1500-Gly-Ibuprofen, 
PEG6000-Gly-Ibuprofen, PEG1500-Ketoprofen, 
PEG6000-Ketoprofen, PEG1500-Gly-Ketoprofen and 
PEG6000-Gly-Ketoprofen were characterized by I.R and 
N.M.R and compared with in vitro dissolution studies 
and in vivo analgesic, anti inflammatory and ulcer 
protecting activity. 
In vitro drug release 
The λmax of pure drugs Ibuprofen and Ketoprofen were 
determined and found to be 264 and 256 nm 
respectively. The standard drugs and prodrugs were 
subjected for drug release at pH 1.2 and 7.2 and 37± 0.5
o
 
C individually and % cumulative drug release was noted 
using standard graph. A graph was plotted % cumulative 
drug release v/s time in min. 
Analgesic Activity 
For the study of analgesic activity the models chosen 
were Hotplate method and Acetic acid-induced writhing. 
 Hotplate method 
For the analgesic activity by this method, according to 
Institutional animal ethical committee (IAEC 
1648/PO/a/12/CPCSEA-GCOP-IAEC-03/2013), the rats 
were divided into Six groups consisting of 6 animals 
each and checked for jump response 
31-34
. 
Acetic acid-induced writhing method 
For the study by this method the rats were divided into 6 
groups consisting of 6 animals each. Acetic acid was 
used to induce writhings. Ist group was administered 
acetic acid intra peritoneally and recorded for the onset 
of wriths over a period of 15 minutes and after 3 hrs 
acetic acid was administered and number of wriths were 
noted and compared with control.  
Anti inflammatory Activity 
For assessing anti-inflammatory activity two models 
were chosen  
Carrageenan-induced rat paw edema method 
The animals were divided into 6 groups consisting of 6 
animals each. Before injecting the paw volumes of left 
and right were measured by Dolphin, India 
Plethysmometer and edema volume was noted as Vo and 
after injecting standard drugs and prodrugs the volume 
was noted as Vt. The volume after injection was 
measured at intervals of 1 hr, 3 hr, and 6 hrs. The 
percentage inhibition of edema was calculated by 
equation
31
 
Cotton pellet induced granuloma method 
The rats were divided into 6 groups consisting of 6 
animals each. The rats were anaesthetized with ether, 
incised and then sterilized cotton pellets 10 mg were 
implanted subcutaneously on either side of lumbar 
region. The incision was sutured and each group was 
treated continuously for 7 days with control, standard 
and prodrugs. After 7 days on 8
th
 day, the animals were 
sacrificed and cotton pellets were removed, dried at 
constant weight for 24 hrs and weighed.  
Ulcer Protective Activity 
The method followed for the ulcer protecting activity 
was Pylorus-ligation. Male Sprague-Dawley rats 
weighing 100-150 g were fastened overnight, 
anaesthtized with ether. An incision of 1 cm long in the 
abdomen below the sternum was made and stomach was 
exposed. A thread was passed around pyloric sphincter 
and tied. The rats were kept in separate cages and 
allowed to recover
35
. After 4 hrs of the pylorus ligation 
all the animals including control group were sacrificed, 
abdomen was cut open and entire stomach was removed 
and washed under tap water. Then placed on a glass 
slide and observed on microscope at 10 X magnification 
for ulcers.  
Area of gross damage (ulceration) was measured by 
computerized video analysis system (Metamorph 7.0 
Molecular devices, Downington, PA, USA). Mean ulcer 
score was expressed as Ulcer Index. 
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RESULTS 
 
Figure 2: I.R Spectra of PEG 1500/6000-Ibuprofen 
 
Figure 3: I.R Spectra of PEG 1500/6000-Glycine-
Ibuprofen 
 
Figure 4: I.R Spectra of PEG 1500/6000-Ketoprofen 
 
 
Figure 5: I.R Spectra of PEG 1500/6000-Glycine-
Ketoprofen 
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Figure 6: N.M.R Spectra of PEG 1500/6000-
Ibuprofen 
 
Figure 7: N.M.R Spectra of PEG 1500/6000-Glycine-
Ibuprofen 
 
Figure 8: N.M.R Spectra of PEG 1500/6000-
Ketoprofen 
 
Figure 9: N.M.R Spectra of PEG 1500/6000-Glycine-
Ketoprofen
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Table 1: PEG 1500-Ibuprofen and PEG 1500-Gly-Ibuprofen release at 1.2 & 7.2. 
S.No Time in Minutes PEG 1500-Ibuprofen PEG 1500-Gly-Ibuprofen 
pH 1.2 pH 7.2 pH 1.2 pH 7.2 
1 0 0 0 0 0 
2 5 11.4 12.4 10.9 10.6 
3 10 16.4 24.7 15.4 21.8 
4 15 20.3 38.4 19.2 39.3 
5 30 21.9 46.8 20.6 55.4 
6 45 24.1 69.1 23.7 68.9 
7 60 26.7 81.3 25.4 82.7 
 
 
Figure 10: Cumulative drug release of PEG 1500-Ibuprofen & PEG 1500-Gly-Ibuprofen 
Table 2: PEG 6000-Ibuprofen and PEG 6000-Gly-Ibuprofen release at 1.2 & 7.2. 
S.No Time in Minutes PEG 6000-Ibuprofen PEG 6000-Gly-Ibuprofen 
pH 1.2 pH 7.2 pH 1.2 pH 7.2 
1 0 0 0 0 0 
2 5 8.9 14.2 7.6 15.7 
3 10 10.5 26.9 10.2 29.1 
4 15 15.7 39.6 12.9 49.6 
5 30 20.9 49.2 18.7 59.4 
6 45 22.7 68.7 20.3 72.7 
7 60 26.8 83.8 24.1 84.6 
 
 
Figure 11: Cumulative drug release of PEG 6000-Ibuprofen & PEG 6000-Gly-Ibuprofen 
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Table 3: PEG 1500-Ketoprofen and PEG 1500-Gly-Ketoprofen release at 1.2 & 7.2. 
S.No Time in Minutes PEG 1500-Ketoprofen PEG 1500-Gly-Ketoprofen 
pH 1.2 pH 7.2 pH 1.2 pH 7.2 
1 0 0 0 0 0 
2 5 12.8 16.7 11.4 17.2 
3 10 14.7 29.2 13.8 31.4 
4 15 16.9 38.6 15.7 39.4 
5 30 19.3 46.1 17.8 47.9 
6 45 22.5 68.3 22.9 69.4 
7 60 24.1 84.6 26.7 85.7 
 
 
Figure 12: Cumulative drug release of PEG 1500-Ketoprofen & PEG 1500-Gly-Ketoprofen 
Table 4: PEG 6000-Ketoprofen and PEG 6000-Gly-Ketorpofen release at 1.2 & 7.2. 
S.No Time in Minutes PEG 6000-Ketoprofen PEG 6000-Gly-Ketoprofen 
pH 1.2 pH 7.2 pH 1.2 pH 7.2 
1 0 0 0 0 0 
2 5 11.5 13.7 12.3 12.8 
3 10 15.2 25.8 15.7 20.1 
4 15 17.4 37.8 18.4 36.9 
5 30 19.7 48.7 20.7 46.7 
6 45 20.8 69.7 23.5 68.1 
7 60 23.9 84.7 26.8 86.7 
 
 
Figure 13: Cumulative drug release of PEG 6000-Ketoprofen & PEG 6000-Gly-Ketoprofen 
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Analgesic Activity: Hotplate Method 
Table 5: Analgesic activity of Ibuprofen/Ketoprofen and synthesized prodrugs 
Groups % Inhibition 
Ibuprofen 
% Inhibition 
Ketoprofen 
Control 0 0 
Ibuprofen/ketoprofen 62.0 63.5 
PEG 1500-Ibuprofen/ ketoprofen 65.7 72.3 
PEG 1500-Glycine-Ibuprofen/ ketoprofen 98.3 76.2 
PEG 6000-Ibuprofen/ ketoprofen 73.6 90.3 
PEG 6000-Glycine-Ibuprofen/ ketoprofen 52.8 97.5 
 
 
Acetic acid method 
Table 6: Analgesic activity of Ibuprofen and synthesized prodrugs 
Groups % Inhibition 
Ibuprofen 
% Inhibition 
Ketoprofen 
Control 0 0 
Ibuprofen/Ketoprofen 74.3 68.3 
PEG 1500-Ibuprofen/Ketoprofen 85.8 83.0 
PEG 1500-Glycine-Ibuprofen/Ketoprofen 92.7 88.1 
PEG 6000-Ibuprofen/Ketoprofen 89.0 86.3 
PEG 6000-Glycine-Ibuprofen/Ketoprofen 84.0 92.1 
 
 
Antiinflammatory Activity: Paw edema method 
Table 7: Anti inflammatory activity of Ibuprofen and synthesized prodrugs 
Groups 
Change in Paw volume (ml) mean±SEM & % Inhibition  
1 hr 3 hr 6 hr 
Control 0.47±0.01 0.59±0.01 0.65±0.02 
Ibuprofen 0.24±0.02 (48.93) 0.22±0.01 (62.7) 0.19±0.01 (70.76) 
PEG1500-Ibuprofen 0.19±0.01 (59.57) 0.18±0.02 (69.49) 0.17±0.03 (73.84) 
PEG1500-Gly-Ibuprofen 0.17±0.01 (63.82) 0.13±0.02 (77.96) 0.11±0.02 (83.07) 
PEG6000-Ibuprofen 0.16±0.01 (65.95) 0.09±0.01 (84.74) 0.08±0.01 (87.69) 
PEG6000-Gly-Ibuprofen 0.18±0.01 (61.7) 0.15±0.02 (74.57) 0.14±0.02 (78.46) 
Values are mean ±SEM, n=6, one way ANOVA p<0.05 vs control 
 
Antiinflammatory Activity: Paw edema method 
Table 8: Anti inflammatory activity of Ketoprofen and synthesized prodrugs 
Groups 
Change in Paw volume (ml) mean±SEM & % Inhibition  
1 hr 3 hr 6 hr 
Control 0.47±0.01  0.59±0.01  0.65±0.02  
Ketoprofen 0.23±0.02 (51.06) 0.20±0.01 (66.1) 0.18±0.01 (72.3) 
PEG1500-Ketoprofen 0.16±0.01 (65.95) 0.12±0.02 (79.66) 0.11±0.02 (83.07) 
PEG1500-Gly-Ketoprofen 0.17±0.01 (63.82) 0.15±0.02 (74.57) 0.13±0.02 (80.00) 
PEG6000-Ketoprofen 0.14±0.01 (70.21) 0.09±0.01 (84.74) 0.08±0.02 (87.69) 
PEG6000-Gly-Ketoprofen 0.18±0.01 (61.7) 0.16±0.02 (72.88) 0.15±0.03 (76.92) 
Values are mean ±SEM, n=6, one way ANOVA p<0.05 vs control 
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Cotton pellet method 
Table 9: Anti inflammatory activity of Ibuprofen and Ketoprofen synthesized prodrugs 
Groups % Inhibition 
Ibuprofen 
% Inhibition 
Ketoprofen 
Control 0 0 
Ibuprofen/Ketoprofen 59.5 57.7 
PEG 1500-Ibuprofen/Ketoprofen 68.4 61.8 
PEG 1500-Glycine-Ibuprofen/Ketoprofen 66.5 60.3 
PEG 6000-Ibuprofen/Ketoprofen 69.8 70.0 
PEG6000-Glycine-Ibuprofen/Ketoprofen 65.5 67.0 
 
Ulcer Protecting Activity 
Table 10: Gross Ulcer Index of Ibuprofen and synthesized prodrugs 
S.No Treatment Ulcer Index Ulcer Index 
1.  Control 10 10 
2.  Ibuprofen/Ketoprofen 23 19 
3.  PEG1500-Ibuprofen/Ketoprofen 16 17 
4.  PEG1500-Gly-Ibuprofen/Ketoprofen 12 12 
5.  PEG6000-Ibuprofen/Ketoprofen 18 15 
6.  PEG6000-Gly-Ibuprofen/Ketoprofen 17 10 
 
DISCUSSION 
PEG 1500/6000-IBUPROFEN 
I.R- C-O-C- 1110 cm
-1
, CH str- 2850, 2950 cm
-1
, C-O 
str- 1180 cm
-1
, C=O- 1625, 1670 cm
-1
, Di substituted 
Benzene- 730 cm
-1
, 945 cm
-1
, Aromatic CH- 1254 cm
-1
.  
N.M.R- 0.9-1.2 δ-CH3 protons (m) (9), 1.2-2.5 δ-CH2 
protons (m) , 2.6-2.8 δ CH protons (q) (2), 3.2-7.4 δ- 
Benzene (m) (8). 
PEG 1500/6000-GLYCINE-IBUPROFEN 
I.R- C-O-C- 1080 cm
-1
, CH str- 2850, 2950 cm
-1
, C-O 
str- 1130 cm
-1
, C-C str- 1250 cm
-1
, C=O- 1520, 1530, 
1580, 1600 cm
-1
,  C-N str- 1385 cm
-1
, Aliphatic NH- 
3421, 3440 cm
-1
, Di substituted Benzene- 740 cm
-1
, 950 
cm
-1
, Aromatic CH- 1480 cm
-1
.  
N.M.R- 1.1-1.3 δ-CH3 protons (m) (18), 1.2-1.9 δ-CH2 
protons (m) (62), 3.3 -3.5 δ-CH (q) (4), 4.1-7.3 δ-
Benzene  (m) (8), 3.5 δ-NH (d) (2). 
PEG 1500/6000-KETOPROFEN 
I.R- C-O-C- 1110 cm
-1
, CH str- 2850, 2950 cm
-1
, C-O 
str- 1080 cm
-1
, C=O- 1580, 1600, 1620, 1660 cm
-1
,  Di 
substituted Benzene- 770, 840 cm
-1
, Mono substituted 
Benzene- 750, 950 cm
-1
, Aromatic CH- 1460 cm
-1
. 
N.M.R- 1.1-1.3 δ-CH3 protons (m) (6), 1.4-1.9 δ-CH2 
(m) (53), 2.1-2.3 δ  CH protons (d) (2), 3.4-7.3 δ-
Benzene (m) (18). 
PEG 1500/6000-GLYCINE-KETOPROFEN 
I.R- C-O-C- 1110 cm
-1
, CH str- 2850, 2950 cm
-1
, C-O 
str- 1080 cm
-1
, C=O- 1525, 1535, 1560, 1585, 1600, 
1620 cm
-1
,  C-C str- 1230 cm
-1
, C-N str- 1375 cm
-1
, 
Aliphatic NH-3480, 3530 cm
-1
, Di substituted Benzene- 
740, 930 cm
-1
, Mono substituted Benzene- 730, 980 cm
-
1
, Aromatic CH- 1450 cm
-1
. 
N.M.R- 0.7-1.2 δ-CH3 protons (m) (6), 1.3-1.8 δ-CH2 
protons (m) (71), 1.9-2.0 δ CHprotons (d) (2), 4.1-7.5 δ-
Benzene (m) (18), 3.5-3.7 δ- NH (d) (2). 
DISCUSSION 
Based on the results obtained 
 Of all the prodrugs synthesized the dissolution 
studies revealed that their release was higher at pH 
7.2 rather than at pH 1.2. 
 Out of the prodrugs synthesized PEG 1500-Gly-
Ibuprofen and PEG 6000-Gly-Ketoprofen have 
shown maximum effect by Hotplate method and 
Acetic acid. 
 Among the prodrugs synthesized PEG 6000-
Ibuprofen and PEG 6000-Ketoprofen have shown 
maximum effect at the end of 6 hrs by Rat paw 
edema method and Cotton Pellet Method. 
 Of all the prodrugs synthesized PEG 1500-Gly-
Ibuprofen and PEG 6000-Gly-Ketoprofen have 
shown maximum ulcer index indicating ulcer 
protection as compared to other prodrugs. 
CONCLUSION 
It can be concluded that the synthesized polymeric 
prodrugs had an influence on the drug release pattern 
effectively at pH 7.2 and had good ulcer protecting 
activity and Ketoprofen which is a derivative of 
Ibuprofen had maximum ulcer protecting activity than 
Ibuprofen. 
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